HIA
MRNS

Harbor Investment Advisory’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Harbor Investment Advisory’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-37
Closed -$43 – 1329
2024
Q2 		$43 Hold
37
– – ﹤0.01% 1292
2024
Q1 		$334 Hold
37
– – ﹤0.01% 1270
2023
Q4 		$402 Hold
37
– – ﹤0.01% 1112
2023
Q3 		$298 Hold
37
– – ﹤0.01% 1142
2023
Q2 		$402 Hold
37
– – ﹤0.01% 1287
2023
Q1 		$255 Hold
37
– – ﹤0.01% 1298
2022
Q4 		$147 Hold
37
– – ﹤0.01% 1315
2022
Q3 		$0 Hold
37
– – ﹤0.01% 1419
2022
Q2 		$0 Hold
37
– – ﹤0.01% 1431
2022
Q1 		$0 Hold
37
– – ﹤0.01% 1406
2021
Q4 		$0 Hold
37
– – ﹤0.01% 1389
2021
Q3 		$0 Hold
37
– – ﹤0.01% 1368
2021
Q2 		$1K Hold
37
– – ﹤0.01% 1239
2021
Q1 		$1K Hold
37
– – ﹤0.01% 1237
2020
Q4 		$0 Buy
+37
New +$516 ﹤0.01% 1256

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Harbor Investment Advisory's MRNS Position: Q3 2024 in Review

Harbor Investment Advisory sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2024, closing a stake of 37 shares — an estimated $43 sold.

Harbor Investment Advisory first reported a position in MRNS in Q4 2020 and held it in 15 quarters. The position peaked at $1K in Q2 2021. 75 funds tracked by Wall St. Rank hold MRNS as of Q3 2024.

  • Harbor Investment Advisory reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2024 after selling out during the quarter.
  • Harbor Investment Advisory sold 37 Marinus Pharmaceuticals, Inc shares in Q3 2024, an estimated $43.
  • Harbor Investment Advisory first reported a position in Marinus Pharmaceuticals, Inc in Q4 2020 and held it in 15 quarters.
  • Harbor Investment Advisory's Marinus Pharmaceuticals, Inc position peaked at $1K in Q2 2021.
  • 75 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2024.

Based on Harbor Investment Advisory's 13F filing for Q3 2024, filed 4 Oct 2024.